Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56

Alkermes plc.

2024-Q3 EPS reported $1.30 revenue$1,127,646,000

Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).
LYBALVI sales $74.7M (+47%), VIVITROL $113.7M (+14%), ARISTADA $84.7M.
GAAP net income from continuing ops $92.8M, diluted EPS $0.56; non-GAAP net income $121.4M.
Cash & investments $927.8M; repurchased 4.4M shares for $115.6M in Q3; $200M remaining under buyback.
Company reiterates 2024 financial expectations; advancing ALKS 2680 phase 2 studies in narcolepsy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.